ClinicalTrials.gg
Active, not recruitingNCT06921850Updated Sep 25, 2026

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

A Phase 3 interventional study of Bimekizumab in Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL. Active, not recruiting at 16 sites in 3 countries. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Sep 25, 20262 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
9 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
71st of 139
43 · median 45
Started
2025
with 24 others
Phase 3
24 of 161
3 open now
Primary completion
2026-12
later than 14 of 54 live
Registered
131st of 161
by date
Lead sponsor
6 of 161
UCB Biopharma SRL

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 71st largest by enrollment of the 139 interventional ones that give a count, is one of 25 that started in 2025, is one of 24 in phase 3, reaches primary completion later than 14 of the 54 other live ones, and was the 131st registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 9 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Bimekizumab
  • HS
  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
9 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be 12 to \<18 years of age at the time of /assent, at Tanner stage 2 or more, for the first 8 participants only, followed by also including participants ≥9 to \<18 years of age at Tanner stage 2 or more.
  • Study participant must have a diagnosis of HS for at least 6 months prior to the Baseline Visit.
  • Study participant must have moderate to severe HS, defined as a total of ≥5 inflammatory lesions (ie, the sum of abscesses and inflammatory nodules), as assessed at both the Screening and Baseline Visits.
  • Study participant must have HS lesions present in at least 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or III, as assessed at both the Screening and Baseline Visits.
  • Study participant must have had a history of inadequate response to a course of a systemic antibiotic for treatment of HS
  • Study participant must weigh ≥30kg at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • Study participant has a draining tunnel count of >20 at either the Screening or Baseline Visits.
  • Study participant has experienced primary failure (no response within 12 weeks) to 1 or more IL 17 biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier.
  • Study participant has previously participated in this study or has received previous therapy with bimekizumab.
  • Study participant has a history of IBD or symptoms suggestive of IBD.
  • History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
  • Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
  • Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments
  • Study participant has the presence of active suicidal ideation, or positive suicide behavior,
  • Study participant diagnosed with severe depression in the past 6 months prior to the Screening Visit.
  • Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Study participants will receive a bimekizumab dose which is weight-dependent.

    Drug: Bimekizumab

Interventions

  • Bimekizumab will be administered at pre-specified timepoints.

06

What researchers measure

Primary outcomes

  1. Geometric Mean Plasma bimekizumab concentrations at Week 16

    Plasma samples will be collected prior to dosing for measurement of plasma concentrations of bimekizumab at the specified timepoint.

    Time frame: At Week 16

Secondary outcomes

  1. Exposure-adjusted incidence rate of Treatment- Emergent Adverse Events (TEAEs) during the Initial Treatment Period

    The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. An Adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to IMP.

    Time frame: From Baseline until end of the Initial Treatment Period (up to 16 weeks)

  2. Exposure-adjusted incidence rate of Serious TEAEs during the Initial Treatment Period

    The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. A SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Important medical events

    Time frame: From Baseline until end of the Initial Treatment Period (up to 16 weeks)

  3. Exposure-adjusted incidence rate of TEAEs leading to withdrawal during the Initial Treatment Period

    The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to IMP.

    Time frame: From Baseline until end of the Initial Treatment Period (up to 16 weeks)

  4. Exposure-adjusted incidence rate of Selected Safety Topics of Interest (including incidence of infections [serious, opportunistic, fungal, and TB], IBD, and injection site reactions) over the Initial Treatment Period

    Safety topics of interest for this study include events for which special monitoring will be for infections (serious, opportunistic, fungal, and tuberculosis \[TB\]), inflammatory bowel disease (IBD), and injection site reactions.

    Time frame: Up to Week 16

  5. Mean Change from Baseline in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) at Week 16

    Blood pressure (Systolic Blood Pressure and Diastolic Blood Pressure) will be measured in millimeters of mercury (mmHg).

    Time frame: Baseline and Week 16

  6. Mean Change from Baseline in vital sign (Pulse rate) at Week 16

    Pulse Rate will be measured in beats per minute (beats/min).

    Time frame: Baseline and Week 16

  7. Mean Change from Baseline in Biochemistry Laboratory Analyses (glucose, potassium, sodium, calcium) at Weeks 4,12, and 16

    Glucose, potassium, sodium and calcium will be measured in millimoles per liter (mmol/L).

    Time frame: Baseline, Weeks 4, 12, and 16

  8. Mean Change from Baseline in Biochemistry Laboratory Analyses (total bilirubin and direct bilirubin, total protein, blood urea nitrogen, and creatinine) at Weeks 4,12, and 16

    Biochemistry parameters (total bilirubin and direct bilirubin, total protein, blood urea nitrogen \[BUN\], and creatinine) will be measured in micromols per liter (μmol/L).

    Time frame: Baseline, Weeks 4, 12, and 16

  9. Mean Change from Baseline in Biochemistry Laboratory Analyses (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase) at Weeks 4,12, and 16

    Biochemistry parameters (alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) will be measured in units per liter (U/L).

    Time frame: Baseline, Weeks 4, 12, and 16

  10. Mean Change from Baseline in Hematology Laboratory Analyses (hemoglobin) at Weeks 4,12, and 16

    Hemoglobin will be measured in grams per liter (g/L).

    Time frame: Baseline, Weeks 4, 12, and 16

  11. Mean Change from Baseline in Hematology Laboratory Analyses (hematocrit) at Weeks 4,12, and 16

    Hematocrit will be measured in volume percentage (%) of red blood cells in blood.

    Time frame: Baseline, Weeks 4, 12, and 16

  12. Mean Change from Baseline in Hematology Laboratory Analyses (platelets, leukocytes, neutrophils, lymphocytes, eosinophils, basophils, and monocytes) at Weeks 4, 12, and 16

    Platelets, leukocytes, neutrophils, lymphocytes, eosinophils, basophils, and monocytes will be measured in number of blood cells per liter (10\^9/L)

    Time frame: Baseline, Weeks 4, 12, and 16

  13. Mean Change from Baseline in Hematology Laboratory Analyses (erythrocytes)

    Erythrocytes will be measured in number of red blood cells per liter (10\^12/L).

    Time frame: Baseline, Week 4, 12, and 16

  14. Incidence rate for Positive, Negative, Missing Plasma Anti-Bimekizumab Antibodies at Baseline and Week 16

    Positive, negative, and missing plasma anti-bimekizumab antibodies detection prior to and following IMP administration during the Initial Treatment Period.

    Time frame: Baseline and Week 16

07

Study locations

16 sites
  • Hs0006 50708
    Roseville, California 95661, United States
  • Hs0006 50684
    Sacramento, California 95815, United States
  • Hs0006 50707
    Washington D.C., District of Columbia 20010, United States
  • Hs0006 50199
    Miami, Florida 33136, United States
  • Hs0006 50712
    Bowling Green, Kentucky 42104, United States
  • Hs0006 50178
    Clarkston, Michigan 48346, United States
  • Hs0006 50710
    Fort Gratiot, Michigan 48059, United States
  • Hs0006 50711
    Troy, Michigan 48084, United States
  • Hs0006 50706
    Chapel Hill, North Carolina 27516, United States
  • Hs0006 50202
    Fairborn, Ohio 45324, United States
  • Hs0006 50201
    Arlington, Texas 76011, United States
  • Hs0006 40326
    Berlin, Germany
  • Hs0006 40625
    Lodz, Poland
  • Hs0006 40761
    Warsaw, Poland
  • Hs0006 40095
    Wroclaw, Poland
  • Hs0006 40845
    Wroclaw, Poland
08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 10, 2025
StartActual
Apr 7, 2025
Primary completionEst.
Dec 21, 2026
CompletionEst.
Mar 6, 2029
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites removed
Show 2 removed
  • Hs0006 50175 · Phoenix, United States
  • Hs0006 40747 · Mainz, Germany
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    2 sites removed
    Show 2 removed
    • Hs0006 50175 · Phoenix, United States
    • Hs0006 40747 · Mainz, Germany

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06921850
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Apr 7, 2025
Primary completion
Dec 21, 2026 (estimated)
Completion
Mar 6, 2029 (estimated)
Last update
Sep 25, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion